Proteotech Inc.

Otago Innovation Limited

New Zealand Institute for Crop & Food Research Limited

The Malaghan Institute of Medical Research

National Institute of Water and Atmospheric Research Limited

Lesley Larsen

Alan D Snow

Thomas P Lake

Gerardo M Castillo

Beth P Nguyen

David Samuel Larsen

Virginia J Sanders

Stephen D Lorimer

Rex T Weavers

David Llewellyn Coffen

Charlotte Coffen, Legal Representative

Margaret Anne Brimble

Manfred Weigele

Joel Cummings

Luke A Esposito

F Michael Hudson

Robin Andrew James Smith

Russell James Hewitt

David Rennison

Laura Molly Woods

Joanne Clare Harrison

Jui Thiang Brian Kueh

Morgan Jay-Smith

Gregory Giles

Morgayn Iona Read

Ivan Andrew Sammut

Nathan John Stanley

William Alexander Denny

Paula Y Choi

Nigel Brian Perry

Jacquie Lucille Harper

Brent Raymond Copp

Allison Norrie Pearce

Michael Vivian Berridge

Colette Amirah Godfrey

David S Larsen

D Snow Alan

The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

Carbon monoxide releasing norbornenone compounds

Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

Isolation, purification and synthesis of procyanidin B2 and uses thereof

The use of 3,4,3',4&#x2032;-tetrahydroxychalcone in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies

Compounds, compositions, and methods for the treatment of &#x3b2;-amyloid diseases and synucleinopathies

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Compounds of formula (I) or formula (II) have anti-inflammatory activity and comprise a new class of NSAIDs. The compounds are useful for treating inflammatory diseases or disorders. The invention also provides pharmaceutical compositions containing these compounds, as well as methods of treating inflammatory diseases or disorders using compounds of formula (III) or formula (IV).

Anti-inflammatory compounds

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&#x3b2; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis

Growing community of inventors

Dunedin, New Zealand

Lesley Larsen